UpToDate
Official reprint from UpToDate®
www.uptodate.com ©2017 UpToDate, Inc. and/or its affiliates. All Rights Reserved.

Pulmonary hypertension in children: Classification, evaluation, and diagnosis

Authors
Mary P Mullen, MD, PhD
Thomas Kulik, MD
Section Editors
David R Fulton, MD
George B Mallory, MD
Deputy Editor
Carrie Armsby, MD, MPH

INTRODUCTION

Pulmonary hypertension (PH) is a disease characterized by elevated pulmonary artery pressure, which can result in right ventricular failure. In children, PH is most commonly associated with underlying cardiac or lung disease (eg, bronchopulmonary dysplasia). PH may also be idiopathic or familial. Other causes of PH are rare in childhood (table 1). PH can be associated with considerable risk of morbidity and mortality. Management of children with PH requires a multidisciplinary team with experience and expertise in this area.

The classification, evaluation, and diagnosis of PH in children are reviewed here. Management and prognosis of PH in children is reviewed separately. (See "Pulmonary hypertension in children: Management and prognosis".)

Persistent pulmonary hypertension of the newborn, the pathogenesis of PH, and PH in adults (including adults with congenital heart disease), and Eisenmenger syndrome are reviewed separately:

(See "Persistent pulmonary hypertension of the newborn".)

(See "The epidemiology and pathogenesis of pulmonary arterial hypertension (Group 1)".)

                             
To continue reading this article, you must log in with your personal, hospital, or group practice subscription. For more information on subscription options, click below on the option that best describes you:

Subscribers log in here

Literature review current through: Nov 2017. | This topic last updated: Sep 26, 2017.
The content on the UpToDate website is not intended nor recommended as a substitute for medical advice, diagnosis, or treatment. Always seek the advice of your own physician or other qualified health care professional regarding any medical questions or conditions. The use of this website is governed by the UpToDate Terms of Use ©2017 UpToDate, Inc.
References
Top
  1. Abman SH, Hansmann G, Archer SL, et al. Pediatric Pulmonary Hypertension: Guidelines From the American Heart Association and American Thoracic Society. Circulation 2015; 132:2037.
  2. Hansmann G, Apitz C, Abdul-Khaliq H, et al. Executive summary. Expert consensus statement on the diagnosis and treatment of paediatric pulmonary hypertension. The European Paediatric Pulmonary Vascular Disease Network, endorsed by ISHLT and DGPK. Heart 2016; 102 Suppl 2:ii86.
  3. Pietra GG, Capron F, Stewart S, et al. Pathologic assessment of vasculopathies in pulmonary hypertension. J Am Coll Cardiol 2004; 43:25S.
  4. Drossner DM, Kim DW, Maher KO, Mahle WT. Pulmonary vein stenosis: prematurity and associated conditions. Pediatrics 2008; 122:e656.
  5. Montani D, O'Callaghan DS, Savale L, et al. Pulmonary veno-occlusive disease: recent progress and current challenges. Respir Med 2010; 104 Suppl 1:S23.
  6. Tuder RM, Archer SL, Dorfmüller P, et al. Relevant issues in the pathology and pathobiology of pulmonary hypertension. J Am Coll Cardiol 2013; 62:D4.
  7. de Vries RR, Nikkels PG, van der Laag J, et al. Moyamoya and extracranial vascular involvement: fibromuscular dysplasia? A report of two children. Neuropediatrics 2003; 34:318.
  8. Douwes JM, Berger RM. The maze of vasodilator response criteria. Pediatr Cardiol 2011; 32:245.
  9. Ranchoux B, Antigny F, Rucker-Martin C, et al. Endothelial-to-mesenchymal transition in pulmonary hypertension. Circulation 2015; 131:1006.
  10. Jobe AH, Bancalari E. Bronchopulmonary dysplasia. Am J Respir Crit Care Med 2001; 163:1723.
  11. Cerro MJ, Abman S, Diaz G, et al. A consensus approach to the classification of pediatric pulmonary hypertensive vascular disease: Report from the PVRI Pediatric Taskforce, Panama 2011. Pulm Circ 2011; 1:286.
  12. Kulik TJ, Austin ED. Pulmonary hypertension's variegated landscape: a snapshot. Pulm Circ 2017; 7:67.
  13. SIME F, BANCHERO N, PENALOZA D, et al. Pulmonary hypertension in children born and living at high altitudes. Am J Cardiol 1963; 11:143.
  14. Scherrer U, Allemann Y, Rexhaj E, et al. Mechanisms and drug therapy of pulmonary hypertension at high altitude. High Alt Med Biol 2013; 14:126.
  15. Kholdani C, Fares WH, Mohsenin V. Pulmonary hypertension in obstructive sleep apnea: is it clinically significant? A critical analysis of the association and pathophysiology. Pulm Circ 2015; 5:220.
  16. Kulik TJ. Pulmonary blood flow and pulmonary hypertension: Is the pulmonary circulation flowophobic or flowophilic? Pulm Circ 2012; 2:327.
  17. Montani D, Seferian A, Savale L, et al. Drug-induced pulmonary arterial hypertension: a recent outbreak. Eur Respir Rev 2013; 22:244.
  18. Galiè N, Humbert M, Vachiery JL, et al. 2015 ESC/ERS Guidelines for the diagnosis and treatment of pulmonary hypertension: The Joint Task Force for the Diagnosis and Treatment of Pulmonary Hypertension of the European Society of Cardiology (ESC) and the European Respiratory Society (ERS): Endorsed by: Association for European Paediatric and Congenital Cardiology (AEPC), International Society for Heart and Lung Transplantation (ISHLT). Eur Respir J 2015; 46:903.
  19. Law YM, Mack CL, Sokol RJ, et al. Cardiopulmonary manifestations of portovenous shunts from congenital absence of the portal vein: pulmonary hypertension and pulmonary vascular dilatation. Pediatr Transplant 2011; 15:E162.
  20. Khaderi S, Khan R, Safdar Z, et al. Long-term follow-up of portopulmonary hypertension patients after liver transplantation. Liver Transpl 2014; 20:724.
  21. Pepke-Zaba J, Hoeper MM, Humbert M. Chronic thromboembolic pulmonary hypertension: advances from bench to patient management. Eur Respir J 2013; 41:8.
  22. Humbert M, Ghofrani HA. The molecular targets of approved treatments for pulmonary arterial hypertension. Thorax 2016; 71:73.
  23. Machado RD, Southgate L, Eichstaedt CA, et al. Pulmonary Arterial Hypertension: A Current Perspective on Established and Emerging Molecular Genetic Defects. Hum Mutat 2015; 36:1113.
  24. Nasim MT, Ogo T, Ahmed M, et al. Molecular genetic characterization of SMAD signaling molecules in pulmonary arterial hypertension. Hum Mutat 2011; 32:1385.
  25. Simonneau G, Gatzoulis MA, Adatia I, et al. Updated clinical classification of pulmonary hypertension. J Am Coll Cardiol 2013; 62:D34.
  26. van Loon RL, Roofthooft MT, Hillege HL, et al. Pediatric pulmonary hypertension in the Netherlands: epidemiology and characterization during the period 1991 to 2005. Circulation 2011; 124:1755.
  27. Lammers AE, Adatia I, Cerro MJ, et al. Functional classification of pulmonary hypertension in children: Report from the PVRI pediatric taskforce, Panama 2011. Pulm Circ 2011; 1:280.
  28. Moledina S, Hislop AA, Foster H, et al. Childhood idiopathic pulmonary arterial hypertension: a national cohort study. Heart 2010; 96:1401.
  29. Berger RM, Beghetti M, Humpl T, et al. Clinical features of paediatric pulmonary hypertension: a registry study. Lancet 2012; 379:537.
  30. Beghetti M, Galiè N. Eisenmenger syndrome a clinical perspective in a new therapeutic era of pulmonary arterial hypertension. J Am Coll Cardiol 2009; 53:733.
  31. Kulik TJ. Pulmonary hypertension caused by pulmonary venous hypertension. Pulm Circ 2014; 4:581.
  32. Pogoriler JE, Kulik TJ, Casey AM, et al. Lung Pathology in Pediatric Pulmonary Vein Stenosis. Pediatr Dev Pathol 2016; 19:219.
  33. Krishnan U, Feinstein JA, Adatia I, et al. Evaluation and Management of Pulmonary Hypertension in Children with Bronchopulmonary Dysplasia. J Pediatr 2017; 188:24.
  34. Joshi S, Wilson DG, Kotecha S, et al. Cardiovascular function in children who had chronic lung disease of prematurity. Arch Dis Child Fetal Neonatal Ed 2014; 99:F373.
  35. Poon CY, Edwards MO, Kotecha S. Long term cardiovascular consequences of chronic lung disease of prematurity. Paediatr Respir Rev 2013; 14:242.
  36. Khemani E, McElhinney DB, Rhein L, et al. Pulmonary artery hypertension in formerly premature infants with bronchopulmonary dysplasia: clinical features and outcomes in the surfactant era. Pediatrics 2007; 120:1260.
  37. Barst RJ, Ivy DD, Gaitan G, et al. A randomized, double-blind, placebo-controlled, dose-ranging study of oral sildenafil citrate in treatment-naive children with pulmonary arterial hypertension. Circulation 2012; 125:324.
  38. Beghetti M, Berger RM, Schulze-Neick I, et al. Diagnostic evaluation of paediatric pulmonary hypertension in current clinical practice. Eur Respir J 2013; 42:689.
  39. Nakatsuji A, Miyauchi Y, Iwasaki YK, et al. Detection and Evaluation of Pulmonary Hypertension by a Synthesized Right-Sided Chest Electrocardiogram. J Nippon Med Sch 2015; 82:136.
  40. Ploegstra MJ, Zijlstra WM, Douwes JM, et al. Prognostic factors in pediatric pulmonary arterial hypertension: A systematic review and meta-analysis. Int J Cardiol 2015; 184:198.
  41. Kheyfets VO, Dunning J, Truong U, et al. Assessment of N-terminal prohormone B-type natriuretic peptide as a measure of vascular and ventricular function in pediatric pulmonary arterial hypertension. Pulm Circ 2015; 5:658.
  42. Ten Kate CA, Tibboel D, Kraemer US. B-type natriuretic peptide as a parameter for pulmonary hypertension in children. A systematic review. Eur J Pediatr 2015; 174:1267.
  43. Pattathu J, Gorenflo M, Hilgendorff A, et al. Genetic testing and blood biomarkers in paediatric pulmonary hypertension. Expert consensus statement on the diagnosis and treatment of paediatric pulmonary hypertension. The European Paediatric Pulmonary Vascular Disease Network, endorsed by ISHLT and DGPK. Heart 2016; 102 Suppl 2:ii36.
  44. Jone PN, Ivy DD. Echocardiography in pediatric pulmonary hypertension. Front Pediatr 2014; 2:124.
  45. Mourani PM, Sontag MK, Younoszai A, et al. Clinical utility of echocardiography for the diagnosis and management of pulmonary vascular disease in young children with chronic lung disease. Pediatrics 2008; 121:317.
  46. Apitz C, Hansmann G, Schranz D. Hemodynamic assessment and acute pulmonary vasoreactivity testing in the evaluation of children with pulmonary vascular disease. Expert consensus statement on the diagnosis and treatment of paediatric pulmonary hypertension. The European Paediatric Pulmonary Vascular Disease Network, endorsed by ISHLT and DGPK. Heart 2016; 102 Suppl 2:ii23.
  47. Kulik TJ, Clark RL, Hasan BS, et al. Pulmonary arterial hypertension: what the large pulmonary arteries tell us. Pediatr Cardiol 2011; 32:759.
  48. Douwes JM, van Loon RL, Hoendermis ES, et al. Acute pulmonary vasodilator response in paediatric and adult pulmonary arterial hypertension: occurrence and prognostic value when comparing three response criteria. Eur Heart J 2011; 32:3137.
  49. Douwes JM, Humpl T, Bonnet D, et al. Acute Vasodilator Response in Pediatric Pulmonary Arterial Hypertension: Current Clinical Practice From the TOPP Registry. J Am Coll Cardiol 2016; 67:1312.
  50. Beghetti M, Schulze-Neick I, Berger RM, et al. Haemodynamic characterisation and heart catheterisation complications in children with pulmonary hypertension: Insights from the Global TOPP Registry (tracking outcomes and practice in paediatric pulmonary hypertension). Int J Cardiol 2016; 203:325.
  51. Douwes JM, Hegeman AK, van der Krieke MB, et al. Six-minute walking distance and decrease in oxygen saturation during the six-minute walk test in pediatric pulmonary arterial hypertension. Int J Cardiol 2016; 202:34.
  52. Resten A, Maitre S, Humbert M, et al. Pulmonary hypertension: CT of the chest in pulmonary venoocclusive disease. AJR Am J Roentgenol 2004; 183:65.
  53. Ismail K, Roberts K, Manning P, et al. OSA and pulmonary hypertension: time for a new look. Chest 2015; 147:847.
  54. International PPH Consortium, Lane KB, Machado RD, et al. Heterozygous germline mutations in BMPR2, encoding a TGF-beta receptor, cause familial primary pulmonary hypertension. Nat Genet 2000; 26:81.
  55. Deng Z, Morse JH, Slager SL, et al. Familial primary pulmonary hypertension (gene PPH1) is caused by mutations in the bone morphogenetic protein receptor-II gene. Am J Hum Genet 2000; 67:737.
  56. Soubrier F, Chung WK, Machado R, et al. Genetics and genomics of pulmonary arterial hypertension. J Am Coll Cardiol 2013; 62:D13.
  57. Smoot LB, Obler D, McElhinney DB, et al. Clinical features of pulmonary arterial hypertension in young people with an ALK1 mutation and hereditary haemorrhagic telangiectasia. Arch Dis Child 2009; 94:506.
  58. Austin ED, Ma L, LeDuc C, et al. Whole exome sequencing to identify a novel gene (caveolin-1) associated with human pulmonary arterial hypertension. Circ Cardiovasc Genet 2012; 5:336.
  59. Eyries M, Montani D, Girerd B, et al. EIF2AK4 mutations cause pulmonary veno-occlusive disease, a recessive form of pulmonary hypertension. Nat Genet 2014; 46:65.
  60. Best DH, Sumner KL, Austin ED, et al. EIF2AK4 mutations in pulmonary capillary hemangiomatosis. Chest 2014; 145:231.